Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis

J. T. Heverhagen; G. A. Krombach; E. Gizewski

doi:10.1055/s-0035-1553365

RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, Table of Contents

Rofo 2014; 186(07): E1
DOI: 10.1055/s-0035-1553365

Erratum

Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis

Anwendung von extrazellulären gadoliniumhaltigen MR-Kontrastmitteln und Risiko der Nephrogenen Systemischen Fibrose

J. T. Heverhagen

¹University Institute of Diagnostic, Interventional and Pediatric Radiology, Inselspital, University Hospital Bern, Bern

,

G. A. Krombach

²Diagnostic and Interventional Radiology, University Hospital Giessen, Justus Liebig University Giessen, Gießen

,

E. Gizewski

³Department for Neuroradiology, Innsbruck Medical University, Innsbruck

› Author Affiliations

Abstract

Full Text

PDF Download

Erratum (2.7.2015) to: “Application of Extracellular Gadolinium-based MRI Contrast Agents and the Risk of Nephrogenic Systemic Fibrosis. Heverhagen JT et al. Fortschr Röntgenstr 2014; 186: 661 – 669”

We apologize for a translation error in the English version of this article. The sentence “The result is the following groups: gadopentetate dimeglumine, gadodiamide, gadoversetamide belong to Group I “Agents associated with the greatest number of NSF cases; (...)” was corrected with the correct term “gadopentetate”.”